Efficacy and in vitro pharmacological assessment of novel N -hydroxypyridinediones as hepatitis B virus ribonuclease H inhibitors
Antimicrobial Agents and Chemotherapy · 2025
DOI: 10.1128/aac.01455-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025. Verfasst von Molly E Woodson und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Microbiology and Immunology, St. Louis University School of Medicine, St. Louis, Missouri, USA. Hauptthemen laut MEDLINE: Hepatitis B virus, Antiviral Agents, Ribonuclease H, Pyridones. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIH HHS, Gilead Sciences (Gilead).
Abstract (Originalsprache)
We previously reported N -hydroxypyridinedione (HPD) compounds with mid-nanomolar efficacy and selectivity indexes around 300 against hepatitis B virus (HBV) replication. However, they lack pharmacological evaluation. Here, we report in vitro anti-HBV efficacy, cytotoxicity, and pharmacological characterization of 29 novel HPDs within seven subgroups. The best two compounds had EC 50 s of 61 and 190 nM and selectivity indexes of 526 and 1,071. Compounds with one halogen on the major R group were most effective and compounds with large ether R groups were most cytotoxic. Compounds were not cytotoxic in primary human hepatocytes. All compounds were freely soluble in pHs reflecting plasma (7.4) and the gastrointestinal tract (5 and 6.5). Almost all highly soluble compounds were passively permeable at pH 5.0 and 7.4. Only 2 of 11 compounds tested were likely to be effluxed by p-glycoprotein. The most potent HPDs inhibited HBV replication over human ribonuclease H1 activity by 10-fold. Four of 19 compounds inhibited CYP2D6 >50%, but their CYP2D6 IC 50 s were >8× higher than their anti-HBV EC 50 . No compound substantially inhibited CYP3A4. Thirteen of 15 compounds had human microsomal half-lives >30 min with medium to low rates of intrinsic clearance. Eleven of 12 compounds bound plasma proteins by ≥80%; however, effects against HBV replication for only one would likely be physiologically relevant. These results identify two lead candidate HPDs with pharmacological characteristics resembling commercially available drugs that are suitable for in vivo pharmacological and efficacy studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Microbiology and Immunology, St. Louis University School of Medicine, St. Louis, Missouri, USA.
- Institute for Drug and Biotherapeutic Innovation, St. Louis University, St. Louis, Missouri, USA.
- Division of Pharmaceutical Chemistry, Department of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, Panepistimiopolis Zografou, Athens, Greece.
ORCID-Profile: Grigoris Zoidis, John E Tavis
Förderung
- NIAID NIH HHS
- NIH HHS
- Gilead Sciences (Gilead)
- HHS | National Institutes of Health
Zitieren
APA
Woodson, M. E., Walden, H. F., Mottaleb, M. A., Makri, M., Prifti, G. M., Moianos, D., Pardali, V., Zoidis, G., & Tavis, J. E. (2025). Efficacy and in vitro pharmacological assessment of novel N -hydroxypyridinediones as hepatitis B virus ribonuclease H inhibitors. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01455-24
Vancouver
Woodson ME, Walden HF, Mottaleb MA, Makri M, Prifti GM, Moianos D, et al. Efficacy and in vitro pharmacological assessment of novel N -hydroxypyridinediones as hepatitis B virus ribonuclease H inhibitors. Antimicrobial Agents and Chemotherapy. 2025. doi:10.1128/aac.01455-24
BibTeX
@article{Woodson2025,
author = {Woodson, Molly E and Walden, Holly F and Mottaleb, M Abdul and Makri, Maria and Prifti, Georgia-Myrto and Moianos, Dimitrios and Pardali, Vasiliki and Zoidis, Grigoris and Tavis, John E},
title = {Efficacy and in vitro pharmacological assessment of novel N -hydroxypyridinediones as hepatitis B virus ribonuclease H inhibitors},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2025},
doi = {10.1128/aac.01455-24}
}
EUVIMED